MX2019004802A - Determinacion de dosis para los agentes inmunoterapeuticos. - Google Patents
Determinacion de dosis para los agentes inmunoterapeuticos.Info
- Publication number
- MX2019004802A MX2019004802A MX2019004802A MX2019004802A MX2019004802A MX 2019004802 A MX2019004802 A MX 2019004802A MX 2019004802 A MX2019004802 A MX 2019004802A MX 2019004802 A MX2019004802 A MX 2019004802A MX 2019004802 A MX2019004802 A MX 2019004802A
- Authority
- MX
- Mexico
- Prior art keywords
- immunotherapeutic agents
- dose determination
- administration
- variations
- immunotherapeutic
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/56—IFN-alpha
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se relaciona con los métodos para determinar las dosis apropiadas para la administración de compuestos inmunoterapéuticos, en los que la efectividad y la toxicidad pueden variar notablemente con la misma dosis entre individuos por las variaciones naturales de los sujetos individuales, así como las variaciones en la reacción del sistema inmune en respuesta a la administración de dichos compuestos inmunoterapéuticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2016/075647 WO2018077385A1 (en) | 2016-10-25 | 2016-10-25 | Dose determination for immunotherapeutic agents |
PCT/EP2017/077293 WO2018077942A1 (en) | 2016-10-25 | 2017-10-25 | Dose determination for immunotherapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019004802A true MX2019004802A (es) | 2020-02-05 |
Family
ID=57288372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019004802A MX2019004802A (es) | 2016-10-25 | 2017-10-25 | Determinacion de dosis para los agentes inmunoterapeuticos. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20200191798A1 (es) |
EP (1) | EP3532844A1 (es) |
JP (2) | JP7203721B2 (es) |
KR (3) | KR20230035691A (es) |
CN (2) | CN109891238A (es) |
AU (1) | AU2017350137B2 (es) |
BR (1) | BR112019007132A8 (es) |
CA (1) | CA3040203A1 (es) |
MX (1) | MX2019004802A (es) |
WO (2) | WO2018077385A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110305841B (zh) * | 2019-07-12 | 2020-08-25 | 赛德特生物科技开发有限公司 | 可以清除体内隐性感染的免疫细胞及其制备方法与应用 |
WO2023006920A1 (en) | 2021-07-29 | 2023-02-02 | BioNTech SE | Compositions and methods for treatment of melanoma |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
WO1997024447A1 (en) | 1996-01-02 | 1997-07-10 | Chiron Corporation | Immunostimulation mediated by gene-modified dendritic cells |
US7465446B2 (en) * | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
AU2006341189B2 (en) * | 2006-03-28 | 2013-01-31 | Covsey Vaccines Pty Ltd | Method for treating stage IV melanoma |
ES2470644T3 (es) | 2008-05-26 | 2014-06-24 | Universitt Zrich | Nanopart�culas de protamina/ARN para inmunoestimulaci�n |
GB0920258D0 (en) * | 2009-11-19 | 2010-01-06 | Alligator Bioscience Ab | New medical agents and use thereof |
US9459253B2 (en) * | 2009-12-23 | 2016-10-04 | Cellestis Limited | Assay for measuring cell-mediated immunoresponsiveness |
WO2011130566A2 (en) * | 2010-04-16 | 2011-10-20 | Bellicum Pharmaceuticals, Inc. | Method for treating solid tumors |
CN103228293A (zh) * | 2010-11-30 | 2013-07-31 | 巴拉特生物技术国际有限公司 | 用于在哺乳动物中预防和治疗金迪普拉病毒感染的疫苗制剂 |
WO2013126402A1 (en) * | 2012-02-20 | 2013-08-29 | University Of Virginia Patent Foundation | Composition and methods for treating melanoma |
CA2884704C (en) * | 2012-09-07 | 2023-04-04 | Randolph J. Noelle | Vista modulators for diagnosis and treatment of cancer |
EP2943202A4 (en) * | 2013-01-10 | 2016-08-24 | Nimbus Iris Inc | IRAQ INHIBITORS AND USES THEREOF |
CN103417956A (zh) * | 2013-07-23 | 2013-12-04 | 尹先哲 | Cik细胞与中等剂量白介素-2回输联合序贯化疗治晚期非小细胞肺癌的应用 |
CN104800243B (zh) * | 2014-01-28 | 2021-04-30 | 中国人民解放军军事医学科学院基础医学研究所 | 一种重组间充质干细胞在制备免疫抑制剂中的应用 |
WO2016155809A1 (en) * | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
-
2016
- 2016-10-25 WO PCT/EP2016/075647 patent/WO2018077385A1/en active Application Filing
-
2017
- 2017-10-25 EP EP17797880.6A patent/EP3532844A1/en active Pending
- 2017-10-25 JP JP2019520795A patent/JP7203721B2/ja active Active
- 2017-10-25 WO PCT/EP2017/077293 patent/WO2018077942A1/en unknown
- 2017-10-25 KR KR1020237007112A patent/KR20230035691A/ko active IP Right Grant
- 2017-10-25 BR BR112019007132A patent/BR112019007132A8/pt unknown
- 2017-10-25 CN CN201780066349.7A patent/CN109891238A/zh active Pending
- 2017-10-25 CN CN202410163141.9A patent/CN118186047A/zh active Pending
- 2017-10-25 KR KR1020197011386A patent/KR20190073376A/ko not_active IP Right Cessation
- 2017-10-25 MX MX2019004802A patent/MX2019004802A/es unknown
- 2017-10-25 KR KR1020237045216A patent/KR20240007297A/ko active Application Filing
- 2017-10-25 US US16/343,624 patent/US20200191798A1/en active Pending
- 2017-10-25 AU AU2017350137A patent/AU2017350137B2/en active Active
- 2017-10-25 CA CA3040203A patent/CA3040203A1/en active Pending
-
2022
- 2022-10-27 JP JP2022172622A patent/JP2023015152A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3040203A1 (en) | 2018-05-03 |
WO2018077942A1 (en) | 2018-05-03 |
RU2019115822A (ru) | 2020-11-27 |
CN118186047A (zh) | 2024-06-14 |
JP7203721B2 (ja) | 2023-01-13 |
KR20230035691A (ko) | 2023-03-14 |
KR20190073376A (ko) | 2019-06-26 |
BR112019007132A8 (pt) | 2022-08-16 |
KR20240007297A (ko) | 2024-01-16 |
RU2019115822A3 (es) | 2020-12-30 |
BR112019007132A2 (pt) | 2019-07-02 |
JP2019537712A (ja) | 2019-12-26 |
AU2017350137B2 (en) | 2024-04-18 |
JP2023015152A (ja) | 2023-01-31 |
AU2017350137A1 (en) | 2019-04-11 |
CN109891238A (zh) | 2019-06-14 |
WO2018077385A1 (en) | 2018-05-03 |
US20200191798A1 (en) | 2020-06-18 |
EP3532844A1 (en) | 2019-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
CY1122804T1 (el) | Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα) | |
CY1120862T1 (el) | Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων | |
PH12020500500A1 (en) | Pyrazolopyrimidinone compounds and uses thereof | |
PH12016501107A1 (en) | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology | |
MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
MY191581A (en) | Anti-pd-1 antibodies | |
WO2015168379A3 (en) | Combination vaccine devices and methods of killing cancer cells | |
MY187540A (en) | Compounds active towards bromodomains | |
EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
MX2017004838A (es) | Composiciones de interleucina-15 y usos de estas. | |
TN2015000402A1 (fr) | Methods for treating crohn's disease using an anti-il23 antibody | |
MX2019009485A (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. | |
EA201892327A1 (ru) | Ингаляционные и назальные бензодиазепины | |
PH12017500348A1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
MX2019004802A (es) | Determinacion de dosis para los agentes inmunoterapeuticos. | |
MX2018004308A (es) | Peptido derivado de foxm1 y vacuna que lo incluye. | |
MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
MX2019014291A (es) | Metodo de tratamiento. | |
NZ721832A (en) | Solid forms of tenofovir | |
PH12017501979A1 (en) | Pharmaceutical compound | |
MX2018004802A (es) | Nuevo adyuvante y composición de vacuna que contiene el mismo. | |
MX2018009218A (es) | Anticuerpos de cgrp y sus usos. | |
TN2018000091A1 (en) | Oxa-diazaspiro compounds having activity against pain | |
TW201613952A (en) | Cdca1-derived peptide and vaccine containing same |